Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.
Year’s Biggest Billion-Dollar Deals Top $64 Billion
by Lisa Phillips | Mar 16, 2015 8:16 pm | Biotechnology, Pharmaceuticals | 0 comments